تحميل...
Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study
BACKGROUND: Bisphosphonates are recommended for use as first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid-induced osteoporosis in children remains un...
محفوظ في:
| الحاوية / القاعدة: | Pediatr Rheumatol Online J |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BioMed Central
2018
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006935/ https://ncbi.nlm.nih.gov/pubmed/29914510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12969-018-0258-5 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|